secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001140361-23-049091
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roche to acquire Telavant for $7.1B upfront; Roivant owns 75% stake
-------------------------------------------------------------------

- Roche pays $7.1B cash at closing plus $150M milestone for rights to RVT-3101 in US and Japan.
- Roivant owns 75% of Telavant and will receive the majority of proceeds; Pfizer owns 25%.
- RVT-3101 showed 36% clinical remission and 50% endoscopic improvement at week 56 in Phase 2b UC trial.
- Roche obtains option to collaborate with Pfizer on a next-generation p40/TL1A bispecific antibody (Phase 1).
- Transaction expected to close in Q4 2023 or Q1 2024, subject to HSR and other conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123049091/0001140361-23-049091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123049091/ef20012978_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-049091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer